In:
PLOS ONE, Public Library of Science (PLoS), Vol. 18, No. 4 ( 2023-4-4), p. e0273202-
Abstract:
In patients with COVID-19 and baseline soluble urokinase plasminogen receptor plasma (suPAR) levels ≥ 6ng/mL, early administration of anakinra, a recombinant interleukin-1 receptor antagonist, may prevent disease progression and death. In case of suPAR testing unavailability, the Severe COvid Prediction Estimate (SCOPE) score may be used as an alternative in guiding treatment decisions. Methods We conducted a monocenter, retrospective cohort study, including patients with SARS-CoV2 infection and respiratory failure. Patients treated with anakinra (anakinra group, AG) were compared to two control groups of patients who did not receive anakinra, respectively with ≥ 6 ng/mL (CG1) and 〈 6 ng/mL (CG2) baseline suPAR levels. Controls were manually paired by age, sex, date of admission and vaccination status and, for patients with high baseline suPAR, propensity score weighting for receiving anakinra was applied. Primary endpoint of the study was disease progression at day 14 from admission, as defined by patient distribution on a simplified version of the 11-point World Health Organization Clinical Progression Scale (WHO-CPS). Results Between July, 2021 and January, 2022, 153 patients were included, among which 56 were treated with off-label anakinra, 49 retrospectively fulfilled prescriptive criteria for anakinra and were assigned to CG1, and 48 presented with suPAR levels 〈 6ng/mL and were assigned to CG2. At day 14, when comparing to CG1, patients who received anakinra had significantly reduced odds of progressing towards worse clinical outcome both in ordinal regression analysis (OR 0.25, 95% CI 0.11–0.54, p 〈 0.001) and in propensity-adjusted multiple logistic regression analysis (OR 0.32, 95% CI 0.12–0.82, p = 0.021) thus controlling for a wide number of covariates. Sensitivities of baseline suPAR and SCOPE score in predicting progression towards severe disease or death at day 14 were similar (83% vs 100%, p = 0.59). Conclusion This real-word, retrospective cohort study confirmed the safety and the efficacy of suPAR-guided, early use of anakinra in hospitalized COVID-19 patients with respiratory failure.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0273202
DOI:
10.1371/journal.pone.0273202.g001
DOI:
10.1371/journal.pone.0273202.g002
DOI:
10.1371/journal.pone.0273202.g003
DOI:
10.1371/journal.pone.0273202.t001
DOI:
10.1371/journal.pone.0273202.t002
DOI:
10.1371/journal.pone.0273202.t003
DOI:
10.1371/journal.pone.0273202.t004
DOI:
10.1371/journal.pone.0273202.s001
DOI:
10.1371/journal.pone.0273202.s002
DOI:
10.1371/journal.pone.0273202.s003
DOI:
10.1371/journal.pone.0273202.s004
DOI:
10.1371/journal.pone.0273202.s005
DOI:
10.1371/journal.pone.0273202.s006
DOI:
10.1371/journal.pone.0273202.s007
DOI:
10.1371/journal.pone.0273202.s008
DOI:
10.1371/journal.pone.0273202.r001
DOI:
10.1371/journal.pone.0273202.r002
DOI:
10.1371/journal.pone.0273202.r003
DOI:
10.1371/journal.pone.0273202.r004
DOI:
10.1371/journal.pone.0273202.r005
DOI:
10.1371/journal.pone.0273202.r006
DOI:
10.1371/journal.pone.0273202.r007
DOI:
10.1371/journal.pone.0273202.r008
DOI:
10.1371/journal.pone.0273202.r009
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2023
detail.hit.zdb_id:
2267670-3
Bookmarklink